Cargando…

Impact of first-line protease inhibitors on predicted resistance to tipranavir in HIV-1-infected patients with virological failure

BACKGROUND: Tipranavir (TPV) is a recently approved nonpeptidic protease inhibitor (PI) of HIV-1 and has been indicated for those infected with PIs-resistant HIV-1. However, in clinical practice, whether the HIV-1 from the patients with virological failure to the regimens containing first-line PIs r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hsieh, Szu-Min, Chang, Sui-Yuan, Hung, Chien-Ching, Sheng, Wang-Huei, Chen, Mao-Yuan, Chang, Shan-Chwen
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2749855/ https://www.ncbi.nlm.nih.gov/pubmed/19751502 http://dx.doi.org/10.1186/1471-2334-9-154

Ejemplares similares

Tipranavir in the Protease Inhibitors Arena
por: Vergani, Barbara, et al.
Publicado: (2012)

Virological Response to Tenofovir Disoproxil Fumarate in HIV-Positive Patients with Lamivudine-Resistant Hepatitis B Virus Coinfection in an Area Hyperendemic for Hepatitis B Virus Infection
por: Huang, Yu-Shan, et al.
Publicado: (2016)

Presence of Tablet Remnants of Nevirapine Extended-Release in Stools and Its Impact on Virological Outcome in HIV-1-Infected Patients: A Prospective Cohort Study
por: Lee, Yi-Chieh, et al.
Publicado: (2015)

Association between amebic liver abscess and Human Immunodeficiency Virus infection in Taiwanese subjects
por: Hsu, Meng-Shuian, et al.
Publicado: (2008)

Review of tipranavir in the treatment of drug-resistant HIV
por: Streeck, Hendrik, et al.
Publicado: (2007)

Prevalence of Integrase Strand Transfer Inhibitors (INSTI) Resistance Mutations in Taiwan
por: Chang, Sui-Yuan, et al.
Publicado: (2016)

Achievements of COVID-19 vaccination programs: Taiwanese perspective
por: Sheng, Wang-Huei, et al.
Publicado: (2023)

Role of tipranavir in treatment of patients with multidrug-resistant HIV
por: Courter, Joshua D, et al.
Publicado: (2010)

A cross-sectional seroprevalence for COVID-19 among healthcare workers in a tertially care hospital in Taiwan
por: Pan, Sung-Ching, et al.
Publicado: (2021)

Serological response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 prime-boost vaccination with a twelve-week interval
por: Sheng, Wang-Huei, et al.
Publicado: (2023)

Evolution of SARS-CoV-2 neutralizing antibody in an HIV-positive patient with COVID-19
por: Liu, Wang-Da, et al.
Publicado: (2021)

Correlation of adverse effects and antibody responses following homologous and heterologous COVID19 prime-boost vaccinations
por: Cheng, Aristine, et al.
Publicado: (2023)

Cost-effectiveness of tipranavir versus comparator protease inhibitor regimens in HIV infected patients previously exposed to antiretroviral therapy in the Netherlands
por: Hubben, Gijs AA, et al.
Publicado: (2007)

Hepatic profile analyses of tipranavir in Phase II and III clinical trials
por: Mikl, Jaromir, et al.
Publicado: (2009)

Serological response after COVID-19 mRNA-1273 booster dose in immunocompromised patients, Taiwan, July to August 2021
por: Lin, Kuan-Yin, et al.
Publicado: (2022)

Immunogenicity and safety of third-dose mRNA COVID-19 vaccines in healthy adults previously vaccinated with two doses of the ChAdOx1 vaccine
por: Sheng, Wang-Huei, et al.
Publicado: (2023)

Effectiveness of COVID-19 vaccination among people living with HIV during a COVID-19 outbreak()
por: Lin, Kuan-Yin, et al.
Publicado: (2022)

Effects of Tipranavir, Darunavir, and Ritonavir on Platelet Function, Coagulation, and Fibrinolysis in Healthy Volunteers
por: Kort, Jens J, et al.
Publicado: (2011)

Effects of enzyme inducers efavirenz and tipranavir/ritonavir on the pharmacokinetics of the HIV integrase inhibitor dolutegravir
por: Song, Ivy, et al.
Publicado: (2014)

Virologic Response to Tipranavir-Ritonavir or Darunavir-Ritonavir Based Regimens in Antiretroviral Therapy Experienced HIV-1 Patients: A Meta-Analysis and Meta-Regression of Randomized Controlled Clinical Trials
por: Berhan, Asres, et al.
Publicado: (2013)

Risk of Active Tuberculosis in HIV-Infected Patients in Taiwan with Free Access to HIV Care and a Positive T-Spot.TB Test
por: Sun, Hsin-Yun, et al.
Publicado: (2015)

FDA-Approved Drugs Efavirenz, Tipranavir, and Dasabuvir Inhibit Replication of Multiple Flaviviruses in Vero Cells
por: Stefanik, Michal, et al.
Publicado: (2020)

Safety and antibody response of recipients who unexpectedly received undiluted prime dose of BNT162b2 COVID-19 vaccine in Taiwan
por: Sheng, Wang-Huei, et al.
Publicado: (2023)

Immune response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 vaccination compared with homologous ChAdOx1-nCoV-19 or homologous mRNA-1273 vaccination
por: Sheng, Wang-Huei, et al.
Publicado: (2022)

Relating protease inhibitor resistance at time of virological failure with drug exposure
por: Van Luin, M, et al.
Publicado: (2010)

Immuno-haematologic and virologic responses and predictors of virologic failure in HIV-1 infected adults on first-line antiretroviral therapy in Cameroon
por: Meriki, Henry D, et al.
Publicado: (2014)

Virologic, clinical and immunologic responses following failure of first-line antiretroviral therapy in Haiti
por: Charles, Macarthur, et al.
Publicado: (2012)

Boosted Tipranavir versus Darunavir in Treatment-Experienced Patients: Observational Data from the Randomized POTENT Trial
por: Elgadi, Mabrouk M., et al.
Publicado: (2012)

Prolonged virus shedding even after seroconversion in a patient with COVID-19
por: Liu, Wang-Da, et al.
Publicado: (2020)

Recently acquired hepatitis C virus infection among people living with human immunodeficiency virus at a university hospital in Taiwan
por: Huang, Miao-Hui, et al.
Publicado: (2021)

Raltegravir, Indinavir, Tipranavir, Dolutegravir, and Etravirine against main protease and RNA-dependent RNA polymerase of SARS-CoV-2: A molecular docking and drug repurposing approach
por: Indu, Purushothaman, et al.
Publicado: (2020)

HIV multi-drug resistance at first-line antiretroviral failure and subsequent virological response in Asia
por: Jiamsakul, Awachana, et al.
Publicado: (2014)

1602. Determinants of Early Virologic Failure Among HIV patients on First-line Antiretroviral Therapy
por: Ramos, Diana G, et al.
Publicado: (2023)

Risk of pneumocystosis after early discontinuation of prophylaxis among HIV-infected patients receiving highly active antiretroviral therapy
por: Cheng, Chien-Yu, et al.
Publicado: (2010)

Durability and Immunogenicity of Neutralizing Antibodies Response Against Omicron Variants After Three Doses of Subunit SARS-CoV-2 Vaccine MVC-COV1901: An Extension to an Open-Label, Dose-Escalation Phase 1 Study
por: Hsieh, Szu-Min, et al.
Publicado: (2022)

Dose-Related Aberrant Inhibition of Intracellular Perforin Expression by S1 Subunit of Spike Glycoprotein That Contains Receptor-Binding Domain from SARS-CoV-2
por: Huang, Chun-Fu, et al.
Publicado: (2021)

Predictors of Virological Failure and Time to Viral Suppression of First-Line Integrase Inhibitor–Based Antiretroviral Treatment
por: Pyngottu, Ashima, et al.
Publicado: (2020)

Outcomes After Switching to BIC/FTC/TAF in Patients with Virological Failure to Protease Inhibitors or Non-Nucleoside Reverse Transcriptase Inhibitors: A Real-World Cohort Study
por: Chang, Hui-Min, et al.
Publicado: (2021)

Effectiveness of Ritonavir-Boosted Protease Inhibitor Monotherapy in Clinical Practice Even with Previous Virological Failures to Protease Inhibitor-Based Regimens
por: López-Cortés, Luis F., et al.
Publicado: (2016)

Virologic Failure of Protease Inhibitor-Based Second-Line Antiretroviral Therapy without Resistance in a Large HIV Treatment Program in South Africa
por: Levison, Julie H., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_2ke1nun1ahsnmh64fa7ubm8l7l